Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection

NCT06544551 is registered in ClinicalTrials.gov with Beijing Kawin Technology Share-Holding Co., Ltd. as lead sponsor.

NCT NCT06544551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06544551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection
Lead sponsor
Beijing Kawin Technology Share-Holding Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 28, 2021
Completion date
December 30, 2023
Enrollment
336 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b virus infection